Antibody Drug Conjugates Market Report by Component (Monoclonal Antibodies, Linker, Cytotoxic Agent, and Others), Target (Antibody-Protein Toxin Conjugates, Antibody-Chelated Radionuclide Conjugates, Antibody-Small-Molecule Drug Conjugates, Antibody-Enzym

Antibody Drug Conjugates Market Report by Component (Monoclonal Antibodies, Linker, Cytotoxic Agent, and Others), Target (Antibody-Protein Toxin Conjugates, Antibody-Chelated Radionuclide Conjugates, Antibody-Small-Molecule Drug Conjugates, Antibody-Enzyme Conjugates), Application (Lymphoma, Ovarian Cancer, Lung Cancer, Breast Cancer, Brain Tumor, and Others), End User (Hospitals, Specialized Cancer Centers, Academic Research Institutes, Biotechnology Companies, and Others), and Region 2024-2032

The global antibody drug conjugates market size reached US$ 7.8 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 43.7 Billion by 2032, exhibiting a growth rate (CAGR) of 20.5% during 2024-2032.

Antibody drug conjugates (ADCs) are highly potent biological drugs comprising tumor-targeting antibodies, which are chemically attached to a cytotoxic effector molecule. They deliver cytotoxic anticancer agents to affected cells by connecting them to monoclonal antibodies (mAb) through biodegradable linkers and allowing sensitive bifurcation between healthy and diseased tissues. They assist in increasing the cell-killing potential of mAb, enhancing drug tolerability, and limiting systematic exposure compared to standard chemotherapy bioactive compounds. At present, they are administered intravenously into the bloodstream to avoid gastric acid and proteolytic enzyme degradation of the mAb.

Antibody Drug Conjugates Market Trends:

Due to sedentary lifestyles and the rising number of individuals who smoke and drink regularly, there is an increase in the prevalence of cancer around the world. This, in confluence with the escalating demand for cost-effective and successful cancer treatments, represents one of the key factors bolstering the growth of the market. Apart from this, the existing linkers often release payloads nonspecifically and lead to off-target toxicity, which severely affects the development of ADCs. As a result, leading players are continuously funding their research and development (R&D) projects to optimize the existing chemical triggers and develop novel chemical triggers to generate highly selective linkers. They are also coming up with novel linker-antibody attachments to produce stable and homogenous ADCs and additional linker-payload attachments to allow the expansion of payloads. Moreover, they are focusing on improving the absorption, distribution, metabolism, and excretion, which is creating a favorable market outlook. Other major factors, including considerably improving healthcare infrastructure, increasing awareness about therapies available for cancer treatments, and the introduction of cleavable linker technology, are anticipated to propel the market growth.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global antibody drug conjugates market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on component, target, application and end user.

Breakup by Component:

• Monoclonal Antibodies
• Linker
• Cytotoxic Agent
• Others

Breakup by Target:

• Antibody-Protein Toxin Conjugates
• Antibody-Chelated Radionuclide Conjugates
• Antibody-Small-Molecule Drug Conjugates
• Antibody-Enzyme Conjugates

Breakup by Application:

• Lymphoma
• Ovarian Cancer
• Lung Cancer
• Breast Cancer
• Brain Tumor
• Others

Breakup by End User:

• Hospitals
• Specialized Cancer Centers
• Academic Research Institutes
• Biotechnology Companies
• Others

Breakup by Region:

• North America
• United States
• Canada
• Asia-Pacific
• China
• Japan
• India
• South Korea
• Australia
• Indonesia
• Others
• Europe
• Germany
• France
• United Kingdom
• Italy
• Spain
• Russia
• Others
• Latin America
• Brazil
• Mexico
• Others
• Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being ADC Therapeutics SA, Astellas Pharma Inc., AstraZeneca plc, Celldex Therapeutics Inc., F. Hoffmann-La Roche AG, Gilead Sciences Inc., GlaxoSmithKline Plc, ImmunoGen Inc, Pfizer Inc., Sanofi S.A., Seagen Inc., Sorrento Therapeutics Inc. and Takeda Pharmaceutical Company Ltd.

Key Questions Answered in This Report:

• How has the global antibody drug conjugates market performed so far and how will it perform in the coming years?
• What has been the impact of COVID-19 on the global antibody drug conjugates market?
• What are the key regional markets?
• What is the breakup of the market based on the component?
• What is the breakup of the market based on the target?
• What is the breakup of the market based on the application?
• What is the breakup of the market based on the end user?
• What are the various stages in the value chain of the industry?
• What are the key driving factors and challenges in the industry?
• What is the structure of the global antibody drug conjugates market and who are the key players?
• What is the degree of competition in the industry?